XML 12 R2.htm IDEA: XBRL DOCUMENT
v3.23.1

Pay vs Performance Disclosure pure in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($)
Pay vs Performance Disclosure [Table] |  |  |
Pay vs Performance [Table Text Block] | Pay Versus Performance Table In accordance with rules adopted by the SEC pursuant to the Dodd-Frank Act, below is disclosure regarding executive compensation for our principal Executive Officer (“PEO,” also known as our CEO), and other NEOs and company financial performance for the fiscal years listed below. The Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown. Pursuant to SEC rules, the information in this “Pay Versus Performance Disclosure” section shall not be deemed to be incorporated by reference into any Celldex filing under the Securities Act or Exchange Act, unless expressly incorporated by specific reference in such filing.
(a) | ​ | ​ | (b) | ​ | ​ | (c) | ​ | ​ | (d) | ​ | ​ | (e) | ​ | ​ | (f) | ​ | ​ | (g) | ​ | ​ | (h) | ​ | ​ | (i) | ​
Fiscal year ended December 31, | ​ | ​ | Summary Compensation Table Total for PEO | ​ | ​ | Compensation Actually Paid to PEO(2) | ​ | ​ | Average Summary Compensation Table Total for Non-PEO NEOs(1) | ​ | ​ | Average Compensation Actually Paid to Non-PEO NEOs(2) | ​ | ​ | Value of Initial Fixed $100 Investment Based on Total Shareholder Return | ​ | ​ | Value of Initial Fixed $100 Investment Based on Peer Group Total Shareholder Return(3) | ​ | ​ | Net Loss (in thousands) | ​ | ​ | Year-end cash & investment balance (in thousands)(4) | ​
2022 | ​ | ​ | ​ | $ | 5,401,283 | ​ | ​ | ​ | ​ | $ | 10,096,324 | ​ | ​ | ​ | ​ | $ | 2,055,757 | ​ | ​ | ​ | ​ | $ | 3,596,459 | ​ | ​ | ​ | ​ | $ | 1,999 | ​ | ​ | ​ | ​ | $ | 153 | ​ | ​ | ​ | ​ | $ | (112,325) | ​ | ​ | ​ | ​ | $ | 304,952 | ​ | ​
2021 | ​ | ​ | ​ | $ | 6,045,894 | ​ | ​ | ​ | ​ | $ | 13,902,770 | ​ | ​ | ​ | ​ | $ | 2,390,179 | ​ | ​ | ​ | ​ | $ | 5,115,872 | ​ | ​ | ​ | ​ | $ | 1,733 | ​ | ​ | ​ | ​ | $ | 137 | ​ | ​ | ​ | ​ | $ | (70,511) | ​ | ​ | ​ | ​ | $ | 408,250 | ​ | ​
2020 | ​ | ​ | ​ | $ | 3,006,668 | ​ | ​ | ​ | ​ | $ | 6,390,027 | ​ | ​ | ​ | ​ | $ | 1,322,858 | ​ | ​ | ​ | ​ | $ | 2,705,672 | ​ | ​ | ​ | ​ | $ | 786 | ​ | ​ | ​ | ​ | $ | 111 | ​ | ​ | ​ | ​ | $ | (59,780) | ​ | ​ | ​ | ​ | $ | 194,422 | ​ | ​
​ (1) As reflected elsewhere herein, our Non-PEO NEOs for 2022 were Tibor Keler, Ph.D., Sam Martin, Margo-Heath Chiozzi, M.D. and Diane C. Young, M.D. Our Non-PEO NEOs for 2021 were Tibor Keler, Ph.D., Freddy Jimenez, Sam Martin and Diane C. Young, M.D. Our Non-PEO NEOs for 2020 were Tibor Keler, Ph.D., Elizabeth Crowley, Margo-Heath Chiozzi, M.D. and Sam Martin. ​ (2) The following table outlines the adjustments made to the compensation earned by the Company’s PEO and other NEOs, as presented in the Summary Compensation Table, to derive the compensation actually paid to the Company’s PEO and other NEOs. ​
​ | ​ | ​ | Adjustments | ​
​ | ​ | ​ | Summary Compensation Table Total | ​ | ​ | Less: Grant Date Fair Value of Option Awards Granted during the Fiscal Year(a) | ​ | ​ | Add: Year-End Fair Value of Outstanding and Unvested Option Awards Granted during the Fiscal Year(b) | ​ | ​ | Adjust for Change in Fair Value of Outstanding and Unvested Option Awards Granted in Prior Fiscal Years(b) | ​ | ​ | Adjust for Change in Fair Value of Option Awards Granted in Prior Fiscal Years that Vested During the Fiscal Year(b) | ​ | ​ | Compensation Actually Paid | ​
PEO | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2022 | ​ | ​ | ​ | $ | 5,401,283 | ​ | ​ | ​ | ​ | ​ | (4,262,250) | ​ | ​ | ​ | ​ | ​ | 9,362,250 | ​ | ​ | ​ | ​ | ​ | 1,051,936 | ​ | ​ | ​ | ​ | ​ | (1,456,895) | ​ | ​ | ​ | ​ | $ | 10,096,324 | ​ | ​
2021 | ​ | ​ | ​ | $ | 6,045,894 | ​ | ​ | ​ | ​ | ​ | (4,868,797) | ​ | ​ | ​ | ​ | ​ | 6,697,600 | ​ | ​ | ​ | ​ | ​ | 3,863,005 | ​ | ​ | ​ | ​ | ​ | 2,165,068 | ​ | ​ | ​ | ​ | $ | 13,902,770 | ​ | ​
2020 | ​ | ​ | ​ | $ | 3,006,668 | ​ | ​ | ​ | ​ | ​ | (1,950,788) | ​ | ​ | ​ | ​ | ​ | 3,516,240 | ​ | ​ | ​ | ​ | ​ | 1,261,828 | ​ | ​ | ​ | ​ | ​ | 556,079 | ​ | ​ | ​ | ​ | $ | 6,390,027 | ​ | ​
Average Non-PEO NEOs | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2022 | ​ | ​ | ​ | $ | 2,055,757 | ​ | ​ | ​ | ​ | ​ | (1,402,280) | ​ | ​ | ​ | ​ | ​ | 3,080,180 | ​ | ​ | ​ | ​ | ​ | 394,595 | ​ | ​ | ​ | ​ | ​ | (531,793) | ​ | ​ | ​ | ​ | $ | 3,596,459 | ​ | ​
2021 | ​ | ​ | ​ | $ | 2,390,179 | ​ | ​ | ​ | ​ | ​ | (1,744,290) | ​ | ​ | ​ | ​ | ​ | 2,399,475 | ​ | ​ | ​ | ​ | ​ | 1,365,289 | ​ | ​ | ​ | ​ | ​ | 705,219 | ​ | ​ | ​ | ​ | $ | 5,115,872 | ​ | ​
2020 | ​ | ​ | ​ | $ | 1,322,858 | ​ | ​ | ​ | ​ | ​ | (759,613) | ​ | ​ | ​ | ​ | ​ | 1,369,181 | ​ | ​ | ​ | ​ | ​ | 536,806 | ​ | ​ | ​ | ​ | ​ | 236,440 | ​ | ​ | ​ | ​ | $ | 2,705,672 | ​ | ​
​ (a) Amounts reflect the aggregate grant-date fair value reported in the “Option Awards” column in the Summary Compensation Table for the applicable year. ​ (b) Fair values as of each measurement date were determined using valuation assumptions and methodologies in accordance with Accounting Standards Codification (ASC) Topic 718. ​ (3) The Peer Group TSR set forth in this table utilizes the NASDAQ Pharmaceutical (Subsector) Index (assuming reinvestment of all dividends), which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K, included in our Annual Report on Form 10-K for the year ended ​ ​ December 31, 2022. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in our company and in the NASDAQ Pharmaceutical (Subsector) Index, respectively, and assumes reinvestment of all dividends. Historical stock performance is not indicative of future stock performance. (4) Our Company Selected Measure is calculated as follows: Year-end cash and investment balance (in thousands), which is calculated by adding the cash, cash equivalents and marketable securities from our consolidated balance sheet. Identifying a Company Selected Measure is a matter of opinion. Other companies, including our peer companies, may utilize different measures as a basis for compensation or may utilize similar measures that are calculated in a manner that is different from the manner in which we calculate that measure. We may change the Company Selected Measure from year to year, depending upon a number of factors relating to our business. |  |
Company Selected Measure Name | Year-end cash & investment balance |  |
Named Executive Officers, Footnote [Text Block] | (1) As reflected elsewhere herein, our Non-PEO NEOs for 2022 were Tibor Keler, Ph.D., Sam Martin, Margo-Heath Chiozzi, M.D. and Diane C. Young, M.D. Our Non-PEO NEOs for 2021 were Tibor Keler, Ph.D., Freddy Jimenez, Sam Martin and Diane C. Young, M.D. Our Non-PEO NEOs for 2020 were Tibor Keler, Ph.D., Elizabeth Crowley, Margo-Heath Chiozzi, M.D. and Sam Martin. |  |
Peer Group Issuers, Footnote [Text Block] | (3) The Peer Group TSR set forth in this table utilizes the NASDAQ Pharmaceutical (Subsector) Index (assuming reinvestment of all dividends), which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K, included in our Annual Report on Form 10-K for the year ended ​ ​ December 31, 2022. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in our company and in the NASDAQ Pharmaceutical (Subsector) Index, respectively, and assumes reinvestment of all dividends. Historical stock performance is not indicative of future stock performance. |  |
PEO Total Compensation Amount | $ 5,401,283 | $ 6,045,894 | $ 3,006,668
PEO Actually Paid Compensation Amount | $ 10,096,324 | 13,902,770 | 6,390,027
Adjustment To PEO Compensation, Footnote [Text Block] | (2) The following table outlines the adjustments made to the compensation earned by the Company’s PEO and other NEOs, as presented in the Summary Compensation Table, to derive the compensation actually paid to the Company’s PEO and other NEOs. ​
​ | ​ | ​ | Adjustments | ​
​ | ​ | ​ | Summary Compensation Table Total | ​ | ​ | Less: Grant Date Fair Value of Option Awards Granted during the Fiscal Year(a) | ​ | ​ | Add: Year-End Fair Value of Outstanding and Unvested Option Awards Granted during the Fiscal Year(b) | ​ | ​ | Adjust for Change in Fair Value of Outstanding and Unvested Option Awards Granted in Prior Fiscal Years(b) | ​ | ​ | Adjust for Change in Fair Value of Option Awards Granted in Prior Fiscal Years that Vested During the Fiscal Year(b) | ​ | ​ | Compensation Actually Paid | ​
PEO | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2022 | ​ | ​ | ​ | $ | 5,401,283 | ​ | ​ | ​ | ​ | ​ | (4,262,250) | ​ | ​ | ​ | ​ | ​ | 9,362,250 | ​ | ​ | ​ | ​ | ​ | 1,051,936 | ​ | ​ | ​ | ​ | ​ | (1,456,895) | ​ | ​ | ​ | ​ | $ | 10,096,324 | ​ | ​
2021 | ​ | ​ | ​ | $ | 6,045,894 | ​ | ​ | ​ | ​ | ​ | (4,868,797) | ​ | ​ | ​ | ​ | ​ | 6,697,600 | ​ | ​ | ​ | ​ | ​ | 3,863,005 | ​ | ​ | ​ | ​ | ​ | 2,165,068 | ​ | ​ | ​ | ​ | $ | 13,902,770 | ​ | ​
2020 | ​ | ​ | ​ | $ | 3,006,668 | ​ | ​ | ​ | ​ | ​ | (1,950,788) | ​ | ​ | ​ | ​ | ​ | 3,516,240 | ​ | ​ | ​ | ​ | ​ | 1,261,828 | ​ | ​ | ​ | ​ | ​ | 556,079 | ​ | ​ | ​ | ​ | $ | 6,390,027 | ​ | ​
Average Non-PEO NEOs | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2022 | ​ | ​ | ​ | $ | 2,055,757 | ​ | ​ | ​ | ​ | ​ | (1,402,280) | ​ | ​ | ​ | ​ | ​ | 3,080,180 | ​ | ​ | ​ | ​ | ​ | 394,595 | ​ | ​ | ​ | ​ | ​ | (531,793) | ​ | ​ | ​ | ​ | $ | 3,596,459 | ​ | ​
2021 | ​ | ​ | ​ | $ | 2,390,179 | ​ | ​ | ​ | ​ | ​ | (1,744,290) | ​ | ​ | ​ | ​ | ​ | 2,399,475 | ​ | ​ | ​ | ​ | ​ | 1,365,289 | ​ | ​ | ​ | ​ | ​ | 705,219 | ​ | ​ | ​ | ​ | $ | 5,115,872 | ​ | ​
2020 | ​ | ​ | ​ | $ | 1,322,858 | ​ | ​ | ​ | ​ | ​ | (759,613) | ​ | ​ | ​ | ​ | ​ | 1,369,181 | ​ | ​ | ​ | ​ | ​ | 536,806 | ​ | ​ | ​ | ​ | ​ | 236,440 | ​ | ​ | ​ | ​ | $ | 2,705,672 | ​ | ​
​ (a) Amounts reflect the aggregate grant-date fair value reported in the “Option Awards” column in the Summary Compensation Table for the applicable year. ​ (b) Fair values as of each measurement date were determined using valuation assumptions and methodologies in accordance with Accounting Standards Codification (ASC) Topic 718. |  |
Non-PEO NEO Average Total Compensation Amount | $ 2,055,757 | 2,390,179 | 1,322,858
Non-PEO NEO Average Compensation Actually Paid Amount | $ 3,596,459 | 5,115,872 | 2,705,672
Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | (2) The following table outlines the adjustments made to the compensation earned by the Company’s PEO and other NEOs, as presented in the Summary Compensation Table, to derive the compensation actually paid to the Company’s PEO and other NEOs. ​
​ | ​ | ​ | Adjustments | ​
​ | ​ | ​ | Summary Compensation Table Total | ​ | ​ | Less: Grant Date Fair Value of Option Awards Granted during the Fiscal Year(a) | ​ | ​ | Add: Year-End Fair Value of Outstanding and Unvested Option Awards Granted during the Fiscal Year(b) | ​ | ​ | Adjust for Change in Fair Value of Outstanding and Unvested Option Awards Granted in Prior Fiscal Years(b) | ​ | ​ | Adjust for Change in Fair Value of Option Awards Granted in Prior Fiscal Years that Vested During the Fiscal Year(b) | ​ | ​ | Compensation Actually Paid | ​
PEO | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2022 | ​ | ​ | ​ | $ | 5,401,283 | ​ | ​ | ​ | ​ | ​ | (4,262,250) | ​ | ​ | ​ | ​ | ​ | 9,362,250 | ​ | ​ | ​ | ​ | ​ | 1,051,936 | ​ | ​ | ​ | ​ | ​ | (1,456,895) | ​ | ​ | ​ | ​ | $ | 10,096,324 | ​ | ​
2021 | ​ | ​ | ​ | $ | 6,045,894 | ​ | ​ | ​ | ​ | ​ | (4,868,797) | ​ | ​ | ​ | ​ | ​ | 6,697,600 | ​ | ​ | ​ | ​ | ​ | 3,863,005 | ​ | ​ | ​ | ​ | ​ | 2,165,068 | ​ | ​ | ​ | ​ | $ | 13,902,770 | ​ | ​
2020 | ​ | ​ | ​ | $ | 3,006,668 | ​ | ​ | ​ | ​ | ​ | (1,950,788) | ​ | ​ | ​ | ​ | ​ | 3,516,240 | ​ | ​ | ​ | ​ | ​ | 1,261,828 | ​ | ​ | ​ | ​ | ​ | 556,079 | ​ | ​ | ​ | ​ | $ | 6,390,027 | ​ | ​
Average Non-PEO NEOs | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2022 | ​ | ​ | ​ | $ | 2,055,757 | ​ | ​ | ​ | ​ | ​ | (1,402,280) | ​ | ​ | ​ | ​ | ​ | 3,080,180 | ​ | ​ | ​ | ​ | ​ | 394,595 | ​ | ​ | ​ | ​ | ​ | (531,793) | ​ | ​ | ​ | ​ | $ | 3,596,459 | ​ | ​
2021 | ​ | ​ | ​ | $ | 2,390,179 | ​ | ​ | ​ | ​ | ​ | (1,744,290) | ​ | ​ | ​ | ​ | ​ | 2,399,475 | ​ | ​ | ​ | ​ | ​ | 1,365,289 | ​ | ​ | ​ | ​ | ​ | 705,219 | ​ | ​ | ​ | ​ | $ | 5,115,872 | ​ | ​
2020 | ​ | ​ | ​ | $ | 1,322,858 | ​ | ​ | ​ | ​ | ​ | (759,613) | ​ | ​ | ​ | ​ | ​ | 1,369,181 | ​ | ​ | ​ | ​ | ​ | 536,806 | ​ | ​ | ​ | ​ | ​ | 236,440 | ​ | ​ | ​ | ​ | $ | 2,705,672 | ​ | ​
​ (a) Amounts reflect the aggregate grant-date fair value reported in the “Option Awards” column in the Summary Compensation Table for the applicable year. ​ (b) Fair values as of each measurement date were determined using valuation assumptions and methodologies in accordance with Accounting Standards Codification (ASC) Topic 718. |  |
Compensation Actually Paid vs. Total Shareholder Return [Text Block] | Relationship between Compensation Actually Paid and TSR The graph below illustrates the relationship between compensation actually paid to the Company’s PEO and other NEOs, our total shareholder return and that of the NASDAQ Pharmaceutical (Subsector) Index. |  |
Compensation Actually Paid vs. Net Income [Text Block] | Relationship between Compensation Actually Paid and Net Loss The graph below illustrates the relationship between compensation actually paid to the Company’s PEO and other NEOs and the Company’s net loss. |  |
Compensation Actually Paid vs. Company Selected Measure [Text Block] | Relationship between Compensation Actually Paid and Year-End Cash & Investment Balance The graph below illustrates the relationship between compensation actually paid to the Company’s PEO and other NEOs and the Company’s year-end cash and investment balance. |  |
Total Shareholder Return Amount | $ 1,999 | 1,733 | 786
Peer Group Total Shareholder Return Amount | 153 | 137 | 111
Net Income (Loss) | $ (112,325,000) | $ (70,511,000) | $ (59,780,000)
Company Selected Measure Amount | 304,952 | 408,250 | 194,422
PEO Name | Anthony S. Marucci. |  |
Measure [Axis]: 1 |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Non-GAAP Measure Description [Text Block] | (4) Our Company Selected Measure is calculated as follows: Year-end cash and investment balance (in thousands), which is calculated by adding the cash, cash equivalents and marketable securities from our consolidated balance sheet. Identifying a Company Selected Measure is a matter of opinion. Other companies, including our peer companies, may utilize different measures as a basis for compensation or may utilize similar measures that are calculated in a manner that is different from the manner in which we calculate that measure. We may change the Company Selected Measure from year to year, depending upon a number of factors relating to our business. |  |
PEO [Member] | Grant Date Fair Value Of Option Awards Granted During The Fiscal Year [Member] |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | $ (4,262,250) | $ (4,868,797) | $ (1,950,788)
PEO [Member] | Year-End Fair Value Of Outstanding And Unvested Option Awards Granted During The Fiscal Year [Member] |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | 9,362,250 | 6,697,600 | 3,516,240
PEO [Member] | Adjust For Change In Fair Value Of Outstanding And Unvested Option Awards Granted In Prior Fiscal Years [Member] |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | 1,051,936 | 3,863,005 | 1,261,828
PEO [Member] | Adjust For Change In Fair Value Of Option Awards Granted In Prior Fiscal Years That Vested During The Fiscal Year [Member] |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | (1,456,895) | 2,165,068 | 556,079
Non-PEO NEO [Member] | Grant Date Fair Value Of Option Awards Granted During The Fiscal Year [Member] |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | (1,402,280) | (1,744,290) | (759,613)
Non-PEO NEO [Member] | Year-End Fair Value Of Outstanding And Unvested Option Awards Granted During The Fiscal Year [Member] |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | 3,080,180 | 2,399,475 | 1,369,181
Non-PEO NEO [Member] | Adjust For Change In Fair Value Of Outstanding And Unvested Option Awards Granted In Prior Fiscal Years [Member] |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | 394,595 | 1,365,289 | 536,806
Non-PEO NEO [Member] | Adjust For Change In Fair Value Of Option Awards Granted In Prior Fiscal Years That Vested During The Fiscal Year [Member] |  |  |
Pay vs Performance Disclosure [Table] |  |  |
Adjustment to Compensation Amount | $ (531,793) | $ 705,219 | $ 236,440

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_NonGaapMeasureDescriptionTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7 Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=cldx_GrantDateFairValueOfOptionAwardsGrantedDuringTheFiscalYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=cldx_YearEndFairValueOfOutstandingAndUnvestedOptionAwardsGrantedDuringTheFiscalYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=cldx_AdjustForChangeInFairValueOfOutstandingAndUnvestedOptionAwardsGrantedInPriorFiscalYearsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=cldx_AdjustForChangeInFairValueOfOptionAwardsGrantedInPriorFiscalYearsThatVestedDuringTheFiscalYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |